Literature DB >> 16521120

The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene.

Michael E Baser1.   

Abstract

Constitutional heterozygous inactivating mutations in the neurofibromatosis 2 (NF2) tumor suppressor gene cause the autosomal dominant disease NF2, and biallelic inactivating somatic NF2 mutations are found in a high proportion of unilateral sporadic vestibular schwannoma (USVS) and sporadic meningioma. We surveyed the distributions of constitutional NF2 mutations in 823 NF2 families, 278 somatic NF2 mutations in USVS, and 208 somatic NF2 mutations in sporadic meningioma. Based on the available NF2 mutation data, the most dominant influence on the spectra of mutations in exons 1-15 are C>T transitions that change arginine codons (CGA) to stop codons (TGA) due to spontaneous deamination of methylcytosine to thymine in CpG dinucleotides. The paucity of reported mutations in exon 9 and the absence of reported mutations in exons 16 and 17 may be related to structure-function relationships in the NF2 protein. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16521120     DOI: 10.1002/humu.20317

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  23 in total

1.  A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.

Authors:  Alejandra M Petrilli; Marisa A Fuse; Mathew S Donnan; Marga Bott; Nicklaus A Sparrow; Daniel Tondera; Julia Huffziger; Corina Frenzel; C Siobhan Malany; Christophe J Echeverri; Layton Smith; Cristina Fernández-Valle
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 2.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

3.  Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.

Authors:  Gilson S Baia; Otavia L Caballero; Brent A Orr; Anita Lal; Janelle S Y Ho; Cynthia Cowdrey; Tarik Tihan; Christian Mawrin; Gregory J Riggins
Journal:  Mol Cancer Res       Date:  2012-05-22       Impact factor: 5.852

4.  Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.

Authors:  Camille Louvrier; Eric Pasmant; Audrey Briand-Suleau; Joëlle Cohen; Patrick Nitschké; Juliette Nectoux; Lucie Orhant; Cécile Zordan; Cyril Goizet; Stéphane Goutagny; Dominique Lallemand; Michel Vidaud; Dominique Vidaud; Michel Kalamarides; Béatrice Parfait
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

5.  WHO grade II and III meningiomas: a study of prognostic factors.

Authors:  Anne Durand; François Labrousse; Anne Jouvet; Luc Bauchet; Michel Kalamaridès; Philippe Menei; Robert Deruty; Jean Jacques Moreau; Michelle Fèvre-Montange; Jacques Guyotat
Journal:  J Neurooncol       Date:  2009-06-27       Impact factor: 4.130

6.  Molecular biology of malignant mesothelioma.

Authors:  Yoshitaka Sekido
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

7.  A deletion causing NF2 exon 9 skipping is associated with familial autosomal dominant intramedullary ependymoma.

Authors:  Ilyess Zemmoura; Patrick Vourc'h; Agathe Paubel; Béatrice Parfait; Joëlle Cohen; Frédéric Bilan; Alain Kitzis; Cécilia Rousselot; Fabrice Parker; Patrick François; Christian R Andres
Journal:  Neuro Oncol       Date:  2013-12-18       Impact factor: 12.300

Review 8.  Targeting Pyk2 for therapeutic intervention.

Authors:  Christopher A Lipinski; Joseph C Loftus
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

9.  Cerebrospinal Fluid Hyaluronan and Neurofibromatosis Type 2.

Authors:  Prasanth S Ariyannur; Narendranath Vikkath; Ashok B Pillai
Journal:  Cancer Microenviron       Date:  2018-08-25

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.